Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1628 • 2018 ACR/ARHP Annual Meeting
Is Axial Psoriatic Arthritis Distinct from Ankylosing Spondylitis with and without Concomitant Psoriasis?
Joy Feld¹, Justine Y. Ye², Vinod Chandran², Robert D Inman³, Nigil Haroon⁴, Richard J. Cook⁵ and Dafna D Gladman¹, ¹Toronto Psoriatic Arthritis Research Program, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, ⁴Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, Toronto, ON, Canada, ⁵Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: Spondyloarthritis include two major phenotypes: ankylosing spondylitis (AS) and psoriatic arthritis (PsA). 10% of AS patients have concomitant psoriasis, while 25% - 70% of…
Abstract Number: 2431 • 2018 ACR/ARHP Annual Meeting
Birth Outcomes and Disease Activity during Pregnancy in a Prospective Cohort of Women with Psoriatic Arthritis and Ankylosing Spondylitis
Chelsey J F Smith¹, Arthur Kavanaugh² and Christina D Chambers³, ¹Rheumatology, University of California San Diego, La Jolla, CA, ²University of California, San Diego, School of Medicine, La Jolla, CA, ³University of California San Diego Department of Pediatrics, La Jolla, CA
Background/Purpose: The goal of this prospective cohort study is to add to the limited data on birth outcomes in psoriatic arthritis (PsA) and ankylosing spondylitis…
Abstract Number: 450 • 2018 ACR/ARHP Annual Meeting
Injection Site Reaction Associated with Subcutaneous Biologic Agents and Methotrexate. Analysis from the Rhumadata® Clinical Database and Registry
Denis Choquette¹, Louis Bessette², Jacques Brown², Boulos Haraoui¹, Frédéric Massicotte¹, Jean-Pierre Pelletier¹, Jean-Pierre Raynauld¹, Marie-Anaïs Rémillard¹, Diane Sauvageau¹, Angèle Turcotte², Édith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ²Rheumatology, Centre de l'Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada
Background/Purpose: Injection Site Reaction (ISRs) are associated with the subcutaneous (SC) route of administration of all biologic agents, and 3% to 15% of patients reports…
Abstract Number: 894 • 2018 ACR/ARHP Annual Meeting
Cancer Risk in Ankylosing Spondylitis in United States Medicare Beneficiaries: Detection of a Chronic Non Steroidal Anti-Inflammatory Drug Use Signature
Sara Alehashemi¹ and Michael Ward², ¹Rheumatology, National Institutes of Health, Bethesda, MD, ²National Institutes of Health, Bethesda, MD, USA, Bethesda, MD
Background/Purpose: Few studies have examined risk of cancer in ankylosing spondylitis (AS) since the end of the radiation therapy era. With greater use of biologics,…
Abstract Number: 1629 • 2018 ACR/ARHP Annual Meeting
Hyperlipoproteinemia (a) in Patients with Spondyloarthritis. Results of the CARMA Study
María Carmen García-Gómez¹, Maria Auxiliadora Martin², Cristina Fernández-Carballido³, Santos Castañeda⁴, Carlos González-Juanatey⁵, Fernando Sánchez-Alonso⁶, María José González-Fernández⁷, Raimon Sanmarti⁸, Alberto Garcia-Vadillo⁹, Benjamin Fernandez Gutierrez¹⁰, Miriam García-Arias¹¹, Javier Manero¹², José Miguel Senabre¹³, Amalia Rueda Cid¹⁴, Sergio Ros Expósito¹⁵, José Manuel Pina Salvador¹⁶, Alba Erra Durán¹⁷, Ingrid Moller¹⁸, Javier Llorca¹⁹ and Miguel Angel González-Gay²⁰, ¹Rheumatology Division, Consorci Sanitari de Terrassa, Terrassa (Barcelona), Spain, ²Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ³Rheumatology Division, Hospital General Universitario de Elda, Elda, Spain, ⁴Rheumatology, Hospital La Princesa. Madrid. Spain, Madrid, Spain, ⁵Division of Cardiology, Hospital Universitario Lucus Augusti, Lugo, Spain, ⁶Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁷Rheumatology, Institut Dexeus, Barcelona, Spain, ⁸Rheumatology Service, Hospital Clinic, Barcelona, Spain, ⁹Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹⁰Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain, ¹¹Hospital Universitario de la Princesa. Madrid. Spain, Madrid, Spain, ¹²Ophthalmology and Rheumatology, Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, ¹³Rheumatology, Hospital Marina Baixa, Alicante, Spain, ¹⁴Rheumatology, Hospital General de Valencia, Valencia, Spain, ¹⁵Rheumatology, Hospital de Viladecans, Barcelona, Spain, ¹⁶Rheumatology, Hospital de Barbastro, Huesca, Spain, ¹⁷Rheumatology, Hospital de Sant Rafael, Barcelona, Spain, ¹⁸Instituto de Poal, Barcelona, Spain, ¹⁹Division of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, Santander, Spain, ²⁰School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain
Background/Purpose: Cardiovascular disease (CVD) is one of the main cause of mortality and morbidity in patients with spondyloarthritis (SpA), partially explained by traditional CV risk…
Abstract Number: 2556 • 2018 ACR/ARHP Annual Meeting
Secukinumab 150mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis with Consistent Safety Profile and High Retention Rate: 4-Year Results from a Phase III Trial
Helena Marzo-Ortega¹, Joachim Sieper², Alan J. Kivitz³, Ricardo Blanco⁴, Martin Cohen⁵, Evie Maria Delicha⁶, Susanne Rohrer⁶ and Hanno Richards⁶, ¹NIHR LBRC, LTHT and LIRMM, University of Leeds, Leeds, United Kingdom, ²University Clinic Benjamin Franklin, Berlin, Germany, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵McGill University, Montreal, QC, Canada, ⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, a fully human monoclonal IgG1 antibody that neutralizes IL-17A, has shown significant and sustained improvement in the signs and symptoms of active ankylosing…
Abstract Number: 512 • 2018 ACR/ARHP Annual Meeting
Incidence of First Cardiovascular Event in Spanish Patients with Chronic Inflammatory Rheumatic Diseases: Prospective Data from an Observational Multicentric Study
Maria Auxiliadora Martin¹, Santos Castañeda², Carlos González-Juanatey³, Fernando Sánchez-Alonso⁴, María Carmen García-Gómez⁵, R López-González⁶, Jesus Babio⁷, Antonio Juan-Mas⁸, María P Moreno-Gil⁹, Olga Sanchez-González¹⁰, Montserrat Romera¹¹, Jose A Pinto-Tasende¹², Jose A Piqueras¹³, Dolores Fábregas¹⁴, Javier Llorca¹⁵ and Miguel Angel González-Gay¹⁶, ¹Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ²Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain, ³Cardiology Division, Hospital Xeral-Calde, Lugo, Spain, ⁴Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁵Rheumatology Division, Consorci Sanitari de Terrassa, Terrassa (Barcelona), Spain, ⁶Rheumatology, Complejo Hospitalario de Zamora. Spain, Zamora, Spain, ⁷Rhaumatology, H General de Cabueñes, Gijon, Spain, ⁸Division of Rheumatology, Hospital Son Llatzer, Palma de Mallorca, Spain, Spain, ⁹Division of Rheumatology, Hospital San Pedro de Alcántara, Cáceres, Spain, ¹⁰Division of Rheumatology, Hospital del Sureste, Madrid, Spain, ¹¹Division of Rheumatology, Hospital de Bellvitge, Barcelona, Spain, ¹²Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ¹³Division of Rheumatology, Hospital Universitario de Guadalajara, Guadalajara, Spain, ¹⁴Division of Rheumatology, Hospital de Barbastro, Huesca, Spain, ¹⁵Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, Santander, Spain, ¹⁶School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain
Background/Purpose: To determine the incidence and risk factors implicated in the development of first cardiovascular event (CVE) in patients with chronic inflammatory rheumatic diseases (CIRD)…
Abstract Number: 895 • 2018 ACR/ARHP Annual Meeting
Associations of Statin Usage with Disease Activity in Ankylosing Spondylitis
Jonathan Dau¹, Lianne S. Gensler², MinJae Lee³, Michael Ward⁴, Matthew Brown⁵, Laura A. Diekman⁶, Mohammad H. Rahbar⁷, Mariko Ishimori⁸, Michael Weisman⁹ and John D. Reveille¹⁰, ¹McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, TX, ²University of California San Francisco, San Francisco, CA, ³Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas-McGovern Medical School, Houston, TX, ⁴National Institutes of Health, Bethesda, MD, USA, Bethesda, MD, ⁵Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia, Brisbane, Australia, ⁶Rheumatology, McGovern Medical School at the University of Texas Health Science Center at Houston, USA, Houston, TX, ⁷Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, McGovern Medical School at the University of Texas Health Science Center at Houston, USA, Houston, TX, ⁸Medicine, Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: Recent studies have shown possible anti-inflammatory effects and a survival benefit with statin usage in ankylosing spondylitis (AS). The purpose of this study was…
Abstract Number: 1630 • 2018 ACR/ARHP Annual Meeting
Do Symptoms of Depression and Anxiety Influence Treatment Response and Long-Term Physical Health Outcomes in Ankylosing Spondylitis?
Carina Lopes^1,2, Mónica Eusébio³, Miguel Bernardes⁴, Patrícia Pinto⁵, Helena Santos⁶, João Lagoas Gomes^1,2, José Tavares Costa⁷, Joao Madruga Dias⁸, Alexandra Bernardo⁹, Lúcia Domingues², Carolina Crespo², Sara Maia², Fernando Martins¹⁰, Jaime Cunha Branco^1,2 and Fernando Pimentel-Santos^1,2, ¹Rheumatology, Hospital de Egas Moniz - Centro Hospitalar Lisboa Ocidental, EPE, Lisbon, Portugal, ²CEDOC, NOVA Medical School, Lisbon, Portugal, ³Sociedade Portuguesa de Reumatologia, Lisboa, Portugal, LIsboa, Portugal, ⁴Rheumatology, Centro Hospitalar de São João, Oporto, Portugal, ⁵Centro Hospitalar Vila Nova de Gaia/Espinho, Gaia, Portugal, ⁶Rheumatology, Instituto Português de Reumatologia, Lisbon, Portugal, ⁷Rheumatology, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, ⁸Centro Hospitalar Médio Tejo, Torres Novas, Portugal, ⁹Centro Hospitalar de São João, Porto, Portugal, ¹⁰Portuguese Society of Rheumatology, Lisbon, Portugal
Background/Purpose: Psychological disturbances, frequently observed in inflammatory rheumatic diseases, seem to negatively influence patient’s clinical status and treatment response. The aim of this study was to examine…
Abstract Number: 2575 • 2018 ACR/ARHP Annual Meeting
Long-Term Effects of TNF-Alpha Inhibitors on Bone Mineral Density and the Incidence of Vertebral Fractures in Patients with Ankylosing Spondylitis
Kim Beek¹, Tamara Rusman², Mignon van der Weijden³, Willem F. Lems⁴, Christiaan van Denderen⁵, Michael T. Nurmohamed⁶ and Irene van der Horst-Bruinsma⁷, ¹Rheumatology, Amsterdam Rheumatology immunology Centre/VUmc and Reade, Amsterdam, Netherlands, ²Rheumatology, VU University medical centre, Amsterdam, Netherlands, ³Rheumatology, Groene Hart Ziekenhuis, Gouda, Netherlands, ⁴Department of Rheumatology, VU Medical Center, Amsterdam, Netherlands, ⁵Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁶Rheumatology, Amsterdam Rheumatology and immunology Center, VU University Medical Center, Amsterdam, Netherlands, ⁷Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Ankylosing Spondylitis (AS) is not only characterized by pathological bone formation leading to ankylosis, but also by bone loss which may lead to vertebral…
Abstract Number: 605 • 2018 ACR/ARHP Annual Meeting
Clinical Outcomes of Golimumab As Second Line TNF Inhibitor Treatment in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Subanalysis of a Non-Interventional Study in Germany
Klaus Krüger¹, Gerd R. Burmester², Siegfried Wassenberg³, Astrid Thiele⁴ and Matthias H. Thomas⁵, ¹Medical Centre of Rheumatology, Munich, Germany, ²Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ³Rheumazentrum Ratingen, Ratingen, Germany, ⁴Krankenhaus St. Josef Wuppertal, Wuppertal, Germany, ⁵Medical Affairs, MSD Sharp & Dohme GmbH, Bünde, Germany
Background/Purpose: Golimumab (GLM) has demonstrated efficacy and safety in patients (pts.) with active RA after treatment with at least one TNFi in a RCT. However,…
Abstract Number: 897 • 2018 ACR/ARHP Annual Meeting
Prevalence of Inflammatory and Chronic Changes Suggestive of Axial Spondyloarthritis in Magnetic Resonance Images of the Axial Skeleton in Individuals < 45 Years in the General Populationas Part of a Large Community Study (SHIP)
Xenofon Baraliakos¹, Daniel Feldmann², Anne Ott², Carsten Oliver Schmidt³, Martin Albers³, Adrian Richter³ and Jürgen Braun¹, ¹Ruhr-University Bochum, Herne, Germany, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany
Background/Purpose: Magnetic resonance imaging (MRI) is crucial for classification and diagnosis of axial spondyloarthritis (axSpA). Characteristic MRI lesions of axSpA are bone marrow edema (BME)…
Abstract Number: 1634 • 2018 ACR/ARHP Annual Meeting
The Impact of Comorbidities on Physical Function in Patients with Ankylosing Spondylitis and Psoriatic Arthritis Attending Rheumatology Clinics. Results of a National Study
Cristina Fernández-Carballido¹, Maria Auxiliadora Martin², María Carmen García-Gómez³, Santos Castañeda⁴, Carlos González-Juanatey⁵, Fernando Sánchez-Alonso⁶, Rosario García-Vicuña⁷, Celia Erausquin⁸, Francisco J Lopez-Longo⁹, María D Sanchez-Gonzalez¹⁰, Alfonso Corrales¹¹, Estefania Quesda-Masachs¹², Eugenio Chamizo Carmona¹³, Carmen Barbadillo¹⁴, Javier Bachiller¹⁵, Tatiana Cobo-Ibáñez¹⁶, Ana Turrión Nieves¹⁷, Emilio Giner Serret¹⁸, Javier Llorca¹⁹ and Miguel Angel González-Gay¹¹, ¹Rheumatology Division, Hospital General Universitario de Elda, Elda, Spain, ²Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ³Rheumatology Division, Consorci Sanitari de Terrassa, Terrassa (Barcelona), Spain, ⁴Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain, ⁵Division of Cardiology, Hospital Universitario Lucus Augusti, Lugo, Spain, ⁶Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁷Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁸Rheumatology, Hospital de Gran Canaria Dr Negrin, Las Palmas GC, Spain, ⁹Rheumatology Department, Hospital Gregorio Marañón, Madrid, Spain, ¹⁰Rheumatology, Hospital Clínico, Salamanca, Spain, ¹¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ¹²Rheumatology Division, Hospital Vall Hebrón, Barcelona, Spain, ¹³Rheumatology, Hospital de Mérida, Merida, Spain, ¹⁴Hospital Universitario Puerta de Hierro, Madrid, Spain, ¹⁵Immuno-Rheumatology research group, IRYCIS. Ramón y Cajal University Hospital, Madrid, Spain, ¹⁶Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, ¹⁷Rheumatology, Hospital Universitario de Salamanca. Spain, Salamanca, Spain, ¹⁸Rheumatology, H Obispo Polanco, Teruel, Spain, ¹⁹Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, Santander, Spain
Background/Purpose: Functional status gets worse with comorbidities regardless of disease activity in patients with rheumatoid arthritis (RA). However, the impact of comorbidities on physical function…
Abstract Number: 2580 • 2018 ACR/ARHP Annual Meeting
Predicting Treatment Persistence and Non-Persistence of Newly Initiated TNF Inhibitor Therapy in Ankylosing Spondylitis Patients: A Gender Comparison
Theresa Hunter¹, Atul A. Deodhar², Rebecca Bolce¹, Krista Schroeder¹ and David Sandoval Calderon¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Oregon Health & Science U, Portland, OR
Background/Purpose: The purpose of this study was to compare treatment patterns in the 2 years following the initiation of TNF inhibitor (TNFi) in AS patients.Methods:…
Abstract Number: 645 • 2018 ACR/ARHP Annual Meeting
Real World Secukinumab Study in Ankylosing Spondylitis and Psoriatic Arthritis – Comorbidities and Extraarticular Manifestations: Incidence and Status throughout a Non-Interventional Study in Germany
Uta Kiltz¹, Peter Kaestner², Holger Krauel², Ilka Schwarze³, Jan Brandt-Juergens⁴, Monika Maier-Peuschel⁵, Carolin Legeler⁵, Justyna Veit⁵ and Hans-Peter Tony⁶, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumatology, Ambulantes Rheumazentrum, Erfurt, Germany, ³Praxis internistische Rheumatologie, Leipzig, Germany, ⁴Rheumatology, Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Rheumatology/Immunology, Medizinische Klinik II, Universitätsklinik, Würzburg, Germany
Background/Purpose: Patients with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) may suffer from extraarticular (EA) manifestations (uveitis, psoriasis) and have higher rates of comorbidities like…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].